Genedata, a provider of software solutions for drug discovery and life science research, has announced that the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP) has selected Genedata Expressionist as the bioinformatics platform for pharmacogenomics and oncology-related translational research.
IKP focuses on improved patient care through personalised medicine. Developing biomarkers that predict drug efficacy as well as drug toxicity, IKP research drives treatment decisions to enhance treatment of patients.
The software provides a platform to process, interpret, and manage terabytes of transcriptomics, genomics, epigenomics, and clinical data from next-generation sequencing (NGS), microarrays, and qPCR experiments.
Genedata Expressionist is an oncology-focused enterprise-level software solution. Genedata Expressionist helps researchers find new drug targets, develop biomarkers for drug response and drug toxicity, and identify new indications or combination therapies for existing drugs. Its data integration capabilities allow researchers to enrich their experiments with genomics data from a wide range of public data repositories.
IKP collaborates with Genedata to further develop and customise Genedata Expressionist to meet the specific requirements of organising and integrating omics data from numerous clinical studies. The collaboration will further focus on the development of analytical workflows that identify driver mutations associated with poor drug response or prognosis
‘With the number of clinical studies employing next-generation technologies rapidly increasing and advancing, we face the challenge of organising, integrating, and interpreting massive amounts of genomic data combined with a large variety of clinical information,’ said Professor Matthias Schwab, head of IKP Stuttgart.
